APP and Alzheimer disease: (2) For 3xTg AD and APP/PS/Tau AD groups, the signal enhancement was significantly different among the five scan-time points in multiple ROI areas, indicating a delayed enhancement compared to a commercially available contrast agent, which is usually not specific in AD diagnosis.